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Background: The rate of bone turnover is closely related to osteoporosis risk. We investigated the correlation
between bone turnover markers and BMD at various skeletal sites in healthy native Chinese women, and to study
the effect of changes in the levels of bone turnover markers on the risk of osteoporosis.
Methods: A cross-section study of 891 healthy Chinese women aged 20–80 years was conducted. The levels of
serum osteocalcin (OC), bone-specific alkaline phosphatase (BAP), serum cross-linked N-terminal telopeptides of type
I collagen (sNTX), cross-linked C-terminal telopeptides of type I collagen (sCTX), urinary NTX (uNTX), urinary CTX
(uCTX) and total urinary deoxypyridinoline (uDPD) were determined. BMD at the posteroanterior spine and the hip
was measured using DXA.
Results: Pearson’s correlation coefficient found significant negative correlation between bone turnover marker and
BMD T-score at different skeletal sites (r = −0.08 to −0.52, all P = 0.038–0.000). After adjustments for age and body
mass index, the partial correlation coefficients between the OC, BAP, sNTX, sCTX and uCTX, and the T-scores at
various skeletal sites were still significant. After adjustment of height and weight, the correlation coefficients
between most BTMs and PA lumbar spine BMD were also significant. Multiple linear regression analysis showed that
bone turnover markers were negative determinants of T-scores. BAP and OC accounted for 33.1% and 7.8% of the
variations in the T-scores of the PA spine, respectively. Serum OC, BAP, uDPD, and sNTX accounted for 0.4–21.9% of
the variations in the femoral neck and total hip T-scores. The bone turnover marker levels were grouped as per
quartile intervals, and the T-scores, osteoporosis prevalence and risk were found to markedly and increase with
increase in bone turnover marker levels.
Conclusions: This study clarified the relationship between bone turnover markers and osteoporosis risk in native
Chinese women. Bone turnover marker levels were found to be important determinants of BMD T-scores.
Furthermore, osteoporotic risk significantly increased with increase in the levels of bone turnover markers.
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Osteoporosis is a common disease, especially in women.
In the USA, 55% of adults aged over 50 years have
osteoporosis, with women accounting for approximately
80% of osteoporotic patients [1]. In Japan, approximately
49% of women aged over 50 years have osteoporosis [2],
whereas in China, an estimated 88 million patients have
primary osteoporosis [3]. Thus, primary osteoporosis is a* Correspondence: wuxp39@sohu.com; eyliao1207@21cn.com
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reproduction in any medium, provided the orconsiderable public health problem in the elderly. In-
crease in the rate of bone turnover is closely related to
an increase in the risk of primary osteoporosis [4], and
bone turnover markers can identify the rate of ongoing
bone turnover. Many studies have shown a correlation
between increased rates of bone loss and increased levels
of bone turnover markers [5-16]. Moreover, changes in
bone turnover markers can predict postmenopausal bone
loss [5,12,17,18] and the risk of osteoporotic fractures
[18-22], especially trabecular bone fractures [21]. Thus,
bone turnover markers are clinically significant, as they
can predict bone loss and osteoporotic risk, help monitor. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of resistance to absorption [22-24]. However, regional and
ethnic differences have been found in the levels of bone
turnover markers and rates of bone loss in women
[25,26]. Furthermore, the relationship of bone turnover
markers with bone mineral density (BMD) T-scores and
the risk and prevalence of osteoporosis has not been clari-
fied in native Chinese women. In order to determine the
nature of this relationship in native Chinese women of
different age groups, we adopted a cross-sectional study
design. In total 891 healthy women living in the central
and southern areas of China underwent tests for bone for-
mation markers, including serum bone-specific alkaline
phosphatase (BAP) and serum osteocalcin (OC), and
bone resorption markers, including serum cross-linked
N-terminal telopeptides of type I collagen (sNTX), serum
cross-linked C-terminal telopeptides of type I collagen
(sCTX), urinary NTX (uNTX), urinary CTX (uCTX) and
total urinary deoxypyridinoline (uDPD). They also under-
went dual energy X ray absorptiometry to determine
BMD of the posteroanterior aspect of the lumbar verte-
brae and proximal femur.
Methods
Study participants
We randomly selected 891 healthy Chinese women, aged
20–80 years, between May 2007 and October 2010. All
the women were residents of Changsha and its surround-
ing regions and were recruited by public health organiza-
tions (i.e., health stations/clinics) that provide health care
for the local residents. All subjects were screened using a
detailed questionnaire, history, and physical examination.
Subjects were excluded from the study if they had condi-
tions that affect bone metabolism, such as diseases of the
kidney, liver, parathyroid, and thyroid, diabetes mellitus,
oligomenorrhea or menopause before the age of 40 years,
hyperprolactinemia, oopherectomy, rheumatoid arthritis,
ankylosing spondylitis, malabsorption syndromes, malig-
nant tumors, hematological diseases, or previous patho-
logical fractures. Subjects were also excluded if they were
being treated with glucocorticoids, estrogens, thyroid hor-
mone, fluorides, bisphosphonates, calcitonin, thiazide di-
uretics, barbiturates, anti-seizure medications, vitamin D,
or calcium-containing drugs. Of the 891 study subjects,
490 were premenopausal, and 401 were postmenopausal
(last menses >12 months before the beginning of the
study). In the latter group, the mean age at menopause
was 48.0 years (range, 40–57 years), and the median dur-
ation of menopause was 9.0 years (range, 1–38 years). The
study was approved by the ethics committee of Xiang-Ya
Medical College, Central South University (China), and all
participants provided written consent to participate.
Blood samples were collected between 7 a.m. and 9 a.m.
after an overnight fast and used to measure the serumlevels of OC, BAP, sNTX and sCTX. Second morning
urine samples were used to measure uNTX, uCTX, total
uDPD and creatinine (Cr). Both serum and urine samples
were stored at −70°C until assayed.
Marker measurements
Enzyme-linked immunosorbent assay (ELISA) kits were
used to measure the serum concentrations of BAP (Metra™
BAP EIA kit, Quidel Corporation, San Diego, CA, USA),
OC (Diagnostic Systems Laboratories Inc., Webster, TX,
USA), sNTX and uNTX (Osteomark, Ostex International
Inc., Seattle, WA, USA), sCTX and uCTX (Nordic Bio-
science Diagnostics A/S, Herlev, Denmark), and uDPD
(Metra™ DPD EIA kit, Quidel Corporation, San Diego, CA,
USA). The concentrations of urinary Cr were measured
using an Auto Biochemistry Analyzer 7170A (Hitachi Co.
Ltd., Tokyo, Japan). The other markers of bone turnover
were measured using a μQuant microplate spectrophotom-
eter (BIO-TEK Instruments Inc., Highland Park, Winooski,
VT, USA). The levels of uNTX, uCTX and uDPD were
corrected using the urinary Cr level. The sNTX level was
expressed as nanomoles of bone collagen equivalents (nM
BCEs) per liter, and the uNTX level was expressed as nM
BCE per millimole creatinine (mM Cr) per liter. The intra-
and inter-assay coefficients of variation (CVs) in order were
as follows: 5.1% and 7.0% for BAP, 5.7% and 7.7% for OC,
4.6% and 6.9% for sNTX, 5.3% and 7.9% for sCTX, 6.1%
and 7.6% for uNTX, 5.6% and 7.1% for uCTX, and 5.9%
and 6.5% for uDPD [27].
BMD was measured with a DXA fan-beam bone densi-
tometer (Hologic Delphi A; Hologic, Bedford, MA, USA)
at various skeletal sites, including the PA lumbar spine
(L1–L4), the femoral neck, and total hip. The in vivo
precision deviations between two repeated BMD mea-
surements at different skeletal sites in 33 subjects were
determined by the root-mean-square CV method [28]
and were 0.83% for the PA lumbar spine, 1.17% for the
femoral neck, and 0.88% for the total hip. The control
spine phantom scan performed each day had a long-
term (>14 years) CV of <0.45%.
Statistical analysis
All calculations were performed using SPSS V17.0 for
Windows software (SPSS Inc., Chicago, IL, USA). The
markers of bone turnover followed a logarithmically nor-
mal distribution and were expressed as the geometrical
mean and SD. The mean values of different parameters
from different groups were compared with each other
for significant differences and were assessed using one-
way analysis of variance (ANOVA) whenever significant
differences were found. Correlations between BMD at dif-
ferent skeletal sites and bone turnover biomarker levels
were made using Pearson’s correlation coefficient and a
partial correlation analysis after adjustments for age and
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performed to determine how much of the variance in
BMD T-scores at different skeletal sites was attributable
to variations in bone biomarker levels. According to the
World Health Organization (WHO) definitions [29] and
the BMD reference databases established by our group
[30], subjects with BMD of 2.5 SD lower (T-scores ≤ −2.5)
than the peak BMD of the same gender were determined
to be osteoporosis. The χ2 test was used to compare the
prevalence of osteoporosis in different quartile groups.Results
Age-related characteristics and parameters
Table 1 shows the age-related basic characteristics, bone
turnover markers and BMD T-scores of the study sub-
jects. The height and urinary creatinine of the subjects
were markedly greater and the body mass index was not-
ably lower in subjects aged 20–29 years and 30–39 years
than in the other subjects. The levels of bone turnover
markers also changed with age. All bone turnover marker
levels were lowest in women aged 30–39 years, the levels
of BAP, OC, uNTX, uCTX and uDPD increased signifi-
cantly in women aged 40–49 years, and all levels increased
further still in women aged over 50 years. The T-scores of
the BMDs at various skeletal sites reduced significantly
after the age of 50–59 years. The T-scores in women aged
60–69 years and 70 or more years were remarkably lower
than the scores in all other age groups.Table 1 Age-related characteristics, bone turnover markers an
Marker
20–29 (n = 124) 30–39 (n = 141) 40–
Height (cm) 158 ± 5.6b 157 ± 5.3b
Weight (kg) 50.1 ± 6.5b 54.3 ± 7.4
BMI (kg/m2) 20.2 ± 2.3b 22.0 ± 2.5b
MSU-Cr (mmol/L) 11.4 ± 5.1b 11.0 ± 5.0b
BAP (U/L)a 16.0 ± 1.3 15.5 ± 1.4 2
OC (μg/L)a 7.3 ± 1.5 4.7 ± 1.6
sNTX (nmol/L)a 13.9 ± 1.3 13.0 ± 1.3
sCTX (mg/L)a 3.7 ± 1.4 2.4 ± 1.6
uNTX (nM BCE/mM Cr)a 33.3 ± 1.6 24.6 ± 1.7 3
uCTX (μg/mM Cr)a 167 ± 1.7 85.1 ± 3.0
uDPD (nM/mM Cr)a 6.1 ± 1.4 4.2 ± 1.8
PA T-score 0.0 ± 0.8 0.1 ± 0.9
FN T-score −0.1 ± 1.1 −0.1 ± 1.2
Hip T-score 0.1 ± 0.9 0.1 ± 0.9
Abbreviations: BMI body mass index, MSU Cr-morning second urinary creatinine, BAP
N-terminal telopeptides of type I collagen (NTX), sCTX serum cross-linked C-termina
uDPD urinary deoxypyridinoline, Cr reatinine, BCE bone collagen equivalents, PA po
geometric mean ± SD. bP = 0.005–0.000 compared with various age groups of ≥40 y
dP = 0.025–0.000 compared with the age groups of 30–39 and 40–49 years. eP = 0.0Correlation between markers and BMD
Table 2 shows in premenopausal and postmenopausal
women after adjusting the height and weight, the correl-
ation coefficients between BMD and various bone turnover
markers. Whether in premenopausal or postmenopausal
women, PA lumbar spine BMD and bone turnover markers
related degree is always better than the FN-BMD and
Hip-BMD. In postmenopausal women, FN-BMD and
Hip-BMD were negatively related to the level of OC,
and showed no significant correlation with other bone
turnover markers. In all of the subjects, there is a negative
relationship between various bone turnover markers and
the BMD T-score (all P = 0.038–0.000) of PA lumbar spine
(r = −0.17 to −0.52), femoral neck (r = −0.08 to −0.44) and
Hip (r = −0.11 to −0.46). Of these, the correlation between
serum OC levels and T-scores at various skeletal sites was
consistently the strongest. After adjustments for age
and BMI, the partial correlation coefficients were mark-
edly lower than the Pearson’s correlation coefficients.
Nonetheless, the partial correlation coefficients of all bone
turnover markers, except for uNTX and uDPD, with the
T-scores at various skeletal sites were significant.Association between markers and T-scores
Figure 1 shows the grouping of the levels of bone turn-
over markers according to quartile intervals, and a com-
parison of the BMD T-scores in the different study
groups. A marked, progressive decrease of T-scores atd T-scores at various skeletal sites
Age (years)
49 (n = 238) 50–59 (n = 229) 60–69 (n = 133) ≥70 (n = 26)
155 ± 5.1 154 ± 4.6 151 ± 5.0 152 ± 4.6
57.5 ± 8.1 56.1 ± 8.5 54.5 ± 8.7 54.4 ± 9.3
23.9 ± 3.0 23.7 ± 3.3 23.7 ± 3.2 23.7 ± 3.7
8.8 ± 4.7 7.7 ± 4.3 7.8 ± 4.4 8.9 ± 5.2
2.0 ± 1.5c 32.1 ± 1.4d 29.1 ± 1.4 25.5 ± 1.4
5.7 ± 1.8c 10.6 ± 1.6d 10.4 ± 1.6 10.2 ± 1.4
13.2 ± 1.5 16.2 ± 1.5d 18.0 ± 1.5 19.0 ± 1.3
2.6 ± 1.9 4.1 ± 1.6d 4.1 ± 1.6 4.9 ± 1.6
3.3 ± 2.2c 60.3 ± 2.2d 49.8 ± 2.2 36.4 ± 1.9
117 ± 2.6c 244 ± 2.2d 235 ± 2.1 193 ± 2.1
5.0 ± 1.8c 6.3 ± 1.6d 6.1 ± 1.7 5.9 ± 1.6
−0.2 ± 1.1 −1.2 ± 1.1d −2.0 ± 1.0e −2.1 ± 1.0e
−0.2 ± 1.2 −1.1 ± 1.2d −2.0 ± 1.0e −2.4 ± 1.0e
0.0 ± 1.0 −0.7 ± 0.9d −1.5 ± 0.8e −1.8 ± 1.0e
bone-specific alkaline phosphatase, OC osteocalcin, sNTX serum cross-linked
l telopeptides of type I collagen (CTX), uNTX urinary NTX, uCTX urinary CTX,
steroanterior spine, FN femoral neck, Hip total hip. aValues are expressed as
ears. cP = 0.032–0.000 compared with the age groups of 30–39 years.
00 compared with various age groups of <60 years.
Table 2 Coefficients of correlation between BMD at various skeletal sites and bone turnover markers corrected for
height and weight in the pre- and postmenopausal women
Marker Premenopausal Postmenopausal
PA-BMD FN-BMD Hip-BMD PA-BMD FN-BMD Hip-BMD
BAP −0.35* −0.16▲ −0.21* −0.30* −0.01 −0.05
OC −0.27* −0.11▲ −0.12▲ −0.30* −0.19▲ −0.22*
sNTX −0.15▲ −0.11▲ −0.08 −0.02 −0.06 −0.08
sCTX −0.20* −0.14▲ −0.07 −0.23* −0.10 −0.10
uNTX −0.05 −0.06 −0.10 −0.09 0.02 −0.01
uCTX −0.16▲ −0.08 −0.07 −0.14▲ −0.01 −0.06
uDPD −0.10 −0.05 −0.03 −0.05 0.10 0.04




































































































































Figure 1 BMD T-scores (mean and SE) at different skeletal sites for native Chinese women, by quartiles of bone turnover markers.
Abbreviations: BAP-bone-specific alkaline phosphatase, OC-osteocalcin, sCTX-serum cross-linked C-terminal telopeptides of type I collagen (CTX),
sNTX-serum cross-linked N-terminal telopeptides of type I collagen, uCTX-urinary CTX, uNTX-urinary NTX, uDPD-urinary deoxypyridinoline,
PA-posteroanterior spine, FN-femoral neck, Q1-first quartile, Q2-second quartile, Q3-third quartile, Q4-fourth quartile. *P = 0.045–0.000 compared
with Q2, Q3 and Q4. ▲P = 0.029–0.000 compared with Q3 and Q4. #P = 0.013–0.000 compared with Q4.
Wu et al. BMC Endocrine Disorders 2014, 14:8 Page 4 of 8
http://www.biomedcentral.com/1472-6823/14/8
Table 3 Multiple linear regression analysis of markers of bone turnover and BMD T-scores at various skeletal sites
Independent PA T-score FN T-score Hip T-score
β Adjusted R2 C (%) β Adjusted R2 C (%) β Adjusted R2 C (%)
BAP −0.39* 33.1 −0.20* 2.8 −0.22* 3.3
OC −0.34* 7.8 −0.35* 20.4 −0.35* 21.9
sNTX ―▲ ―▲ −0.10* 0.7 −0.08* 0.4
sCTX ―▲ ―▲ ―▲ ―▲ ―▲ ―▲
uNTX ―▲ ―▲ ―▲ ―▲ ―▲ ―▲
uCTX ―▲ ―▲ ―▲ ―▲ ―▲ ―▲
uDPD ―▲ ―▲ 0.11* 0.8 0.09* 0.5
Bone turnover markers are identified as independent variables, while BMD T-scores at different skeletal sites are identified as dependent variables. Abbreviations:
as in Table 1, R2 C(%)-R square change. *P = 0.040–0.000. ▲Marker was excluded from this analysis.
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http://www.biomedcentral.com/1472-6823/14/8various skeletal sites was observed with increase in bone
turnover marker levels. Apart from sNTX, sCTX and
uDPD, the remaining bone turnover markers were asso-
ciated with an decreasing tendency of T-scores at vari-
ous skeletal sites in the order of Q1 > Q2 > Q3 > Q4. By
using bone turnover markers as independent variables
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Figure 2 Comparison of prevalence of osteoporosis diagnosed using
by quartiles of bone turnover markers. Abbreviations: as in Figure 1. *P
compared with Q1 and Q2. #P = 0.048–0.000 compared with Q2 and Q3. §Pmultiple linear regression stepwise analysis (Table 3).
The results showed that serum BAP and OC were sig-
nificant negative determinants of the T-score of the PA
spine, and accounted for approximately 33.1% and 7.8%
of the changes in T-scores of the PA spine. Serum OC,
BAP and sNTX were significant negative determinants
of T-scores at femoral neck and total hip.CTX uNTX uCTX uDPD
oanterior spine
TX uNTX uCTX uDPD
emoral neck
BMD T-scores at different skeletal sites in native Chinese women,
= 0.037–0.000 compared with Q1, Q2 and Q3. ▲P = 0.035–0.000
= 0.024–0.001 compared with Q1.
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osteoporosis
Figure 2 shows the grouping of bone turnover markers
according to quartile intervals and a comparison of the
prevalence of osteoporosis among different groups. At
the PA lumbar spine, when BAP, OC, sNTX, sCTX and
uCTX were grouped, the prevalence of osteoporosis in
Q4 group was significantly higher than those in Q1, Q2
and Q3 groups; while, the prevalences of osteoporosis in
Q1 and Q2 groups were significantly lower than Q3
group when OC, sNTX and uCTX were grouped. At the
femoral neck, when BAP, OC and sCTX were grouped
by quartile, the prevalence of osteoporosis in Q4 group
was significantly higher than those in Q1, Q2 and Q3
groups; when OC, uNTX and uCTX were grouped, the
prevalences of osteoporosis in Q1 and Q2 groups were
significantly lower than Q3 group. But there were no sig-
nificant differences between each group when uDPD
was grouped according to quartile.
Table 4 shows the effects of the changes in bone turnover
marker levels on the risks of osteoporosis. The risks forTable 4 Odds ratio (OR) and 95% confidence intervals (CI)
of osteoporosis diagnosed using BMD T-scores at
different skeletal sites in various quartiles (Q) of bone
turnover markers
*Q4/Q1▲ *Q3/Q1▲ *Q4/Q2▲ *Q3/Q2▲
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
BAP categories
PA 13 (6.4–19) 7.8 (3.5–16) 4.1 (2.2–7.6) 1.9 (1.0–3.7)
FN 4.8 (3.3–14) 5.9 (2.2–15) 2.9 (1.6–5.3) 1.6 (0.8–3.0)
OC categories
PA 11 (6.1–18) 5.8 (1.9–13) 6.2 (4.1–17) 3.2 (1.2–8.2)
FN 7.8 (4.9–15) 3.9 (2.6–10) 5.3 (3.2–16) 3.7 (1.6–8.9)
sNTX categories
PA 4.5 (2.2–8.9) 2.3 (1.1–4.9) 7.2 (3.2–16) 3.7 (1.6–8.9)
FN 3.5 (1.7–7.0) 2.4 (1.2–5.2) 2.7 (1.4–5.2) 1.9 (1.0–3.7)
sCTX categories
PA 6.7 (4.6–18) 3.4 (1.1–11) 3.1 (1.7–5.8) 0.8 (0.4–1.7)
FN 5.8 (2.6–13) 1.8 (0.7–4.4) 3.5 (1.8–6.9) 1.1 (0.5–2.4)
uNTX categories
PA 8.9 (3.8–16) 4.9 (2.4–14) 5.1 (2.6–12) 4.0 (1.7–9.6)
FN 4.0 (1.8–9.1) 3.3 (1.5–7.7) 2.9 (1.4–5.9) 2.4 (1.1–5.0)
uCTX categories
PA 8.4 (3.4–15) 4.4 (1.6–12) 4.9 (2.3–10) 2.4 (1.1–5.4)
FN 4.8 (2.1–11) 3.7 (1.5–8.8) 3.3 (1.6–7.1) 2.5 (1.2–5.5)
uDPD categories
PA 3.2 (1.6–6.6) 1.8 (0.8–3.9) 1.8 (1.0–3.3) 1.0 (0.5–1.9)
FN 1.8 (0.9–3.4) 1.1 (0.6–2.3) 1.4 (0.8–2.6) 0.9 (0.5–1.7)
*As the case group, ▲as the control group to calculate ORs. Abbreviations: as
in Table 1 and Figure 1.osteoporosis at various skeletal sites increased with the
levels of bone turnover markers. We calculated odds ratios
(ORs) by using the highest bone turnover marker level in
the Q4 groups (case groups) and the lowest level in the Q1
groups (control groups). In the case of the BAP level, the
risk of osteoporosis of the PA spine and femoral neck in
the Q4 group was 13 times and 4.8 times the risk in the Q1
group, respectively. The corresponding osteoporotic risks
for the OC levels were 11 times and 7.8 times, whereas
those for the sNTX levels were 4.5 times and 3.5 times.
Discussion
Our research confirmed the significant negative correlation
between the levels of bone turnover markers with BMD
and T-scores at various skeletal sites in native Chinese
women; in other words, the BMD and T-scores decreased
as the levels of various bone turnover markers increased.
The best correlation (consistent maximum r values) of
bone turnover markers was seen with the BMD and T-
score of the PA spine. After adjustments for age and BMI,
the partial correlation coefficients between bone turnover
markers and T-scores were lower than the Pearson’s correl-
ation coefficients. With the exception of uNTX and uDPD,
all other bone turnover markers showed statistically signifi-
cant partial correlation coefficients withT-scores. These re-
sults indicate that a varying degree of correlation is present
between individual bone turnover markers and the T-
scores at different skeletal sites. After excluding the influ-
ence of age and BMI, this correlation might reduce. After
adjustment of height and weight, BMD in premenopausal
and postmenopausal women showed significant negative
correlation with bone turnover markers, which was similar
to the results of previous studies [31]. Other studies have
verified that changes in the levels of bone turnover markers
are relevant to bone loss rates in the lumbar vertebrae and
distal end of the forearm [6,13,17,32-38], but not relevant
to bone loss rates in the hip [9,39]. Keen et al. [14] showed
that bone turnover markers are not related to the bone loss
rates in the lumbar spine and the femoral neck. Moreover,
after adjustments for BMI, bone turnover markers, includ-
ing serum OC and uNTX, were not related to bone loss
rates in both the lumbar spine and femoral neck in aged
women [39]. In addition, studies have shown that bone
turnover markers can predict the bone loss rate during
the period of transition to menopause, but not after
menopause [15].
We grouped the levels of bone turnover markers
using quartile intervals and confirmed that the average
T-scores significantly differ among different groups. In
the case of BAP, OC, uNTX and uCTX, progressive in-
crease in marker levels was associated with a marked
and progressive decrease in the average T-scores of the
lumbar spine and femoral neck (Q1 > Q2 > Q3 > Q4). In
the case of the bone resorption markers, the average
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Q2 groups of sNTX and uDPD or between the Q2 and
Q3 groups of sCTX. These results verified that the levels
of bone turnover markers, particularly BAP, OC, uNTX
and uCTX, and the T-scores at various skeletal sites were
closely correlated in native Chinese women. Studies in
other populations have shown that the rate of bone loss is
related to an increase in bone turnover markers in women
[40]. When the levels of bone turnover markers increased
by 1 SD, the risk of rapid bone loss (2.2% per year) in-
creased by 1.8–2.0 times. In subjects in whom the serum
BAP level was 2 SD more than the average level, the prob-
ability of rapid bone loss was 80% [40]. However, when
the serum BAP level was 2 SD less than the average level,
this probability was only 20%.
Multiple linear regression stepwise analysis was used
to compare the effects of the changes in the levels of
various bone turnover markers on the BMD T-scores at
various skeletal sites. Using the T-scores as dependent
variables and bone turnover markers as independent var-
iables, we found that changes in levels of BAP and OC
significantly influenced the T-scores of the PA spine;
these levels jointly accounted for 40.9% of the variations
in the T-scores of the PA spine. Of these markers, BAP
had the largest influence on the T-scores of the PA spine
(33.1%). None of the bone resorption markers had any
effect on the T-scores of the PA spine. Serum OC, BAP
and sNTX jointly accounted for 23.9% and 25.6% of the
variations in the femoral neck and total hip T-scores, re-
spectively. Of these markers, serum OC had the largest in-
fluence on the femoral neck (20.4%) and total hip T-scores
(21.9%). sCTX, uNTX and uCTX had no effect on the
femoral neck and total hip T-scores. Serum BAP was the
greatest determinant of the T-scores of the PA spine, but
serum OC was an important predictive factor of the fem-
oral neck and total hip T-scores. The reasons underlying
these findings might be related to differences in the com-
positions of cortical and cancellous bones. The turnover
of cancellous bones is eight times faster than that of cor-
tical bones [41]. Other studies have reported that serum
OC, uNTX and serum parathyroid hormone (PTH) jointly
account for 43% of the decrease in total hip BMD in aged
women [11]. The combination of bone resorption markers
and bone formation markers or the combination of pyridi-
noline, estrogen and BMI could predict 59% of changes in
the bone loss rate of the forearm [37,42].
Our study confirmed that increase in bone turnover
marker levels was associated with an increase in the preva-
lence and risk of osteoporosis in native Chinese women.
These results show that individuals with increased bone
turnover marker levels, especially BAP, OC, uNTX and
uCTX, have a higher prevalence of osteoporosis. We con-
sidered subjects with high bone turnover marker levels as
the case group and those with low levels as the controlgroup, and calculated that the risk of osteoporosis in-
creased with higher levels of bone turnover markers. This
risk was different for different bone turnover markers and
skeletal sites. For all bone turnover markers other than
uDPD, the risk of osteoporosis of the PA lumbar spine
was 4.5–13 times greater in the Q4 group than in the Q1
group. In the case of the femoral neck, this difference was
3.5–7.8 times. These results also suggest that the risk of
osteoporosis greatly increases with increase in the levels of
bone turnover markers in native Chinese women. In
addition, it is worth pointing out the limitations of this
study, even though the second morning urine creatinine
levels of these subjects were in the reference value range,
but we did not have the simultaneous determination of
their serum creatinine levels and glomerular filtration rate
(eGFR), to investigate the relationship between bone turn-
over markers and eGFR in this study population. Because
the renal function is closely associated with bone metabol-
ism and osteoporosis.
Conclusions
This study revealed a close correlation between bone turn-
over markers and BMD at various skeletal sites in native
Chinese women. The levels of bone turnover markers de-
termine the T-scores at various skeletal sites, and increase
in the levels of these markers was associated with a signifi-
cantly increased risk of osteoporosis. Markers of bone for-
mation, including serum BAP and OC, were the main
determinants of T-scores.
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